EphB receptor-binding peptides

Details EphB receptor-binding peptides EphB receptor-binding peptides

2011-08-16

2011-08-16

Haddad, Maher M (Department: 1644)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C530S325000, C530S326000, C530S327000

Reexamination Certificate

active

07999069

ABSTRACT:
The application is related to the identification of peptides that selectively bind to Eph receptors of the B class. Also disclosed are uses of such peptides in the treatment of a variety of diseases. Additionally, imaging tumors in patients is described by administrating labeled peptides to patients and then obtaining an image of the labeled peptides.

REFERENCES:
patent: 5512457 (1996-04-01), Lyman et al.
patent: 5516658 (1996-05-01), Beckmann et al.
patent: 5624899 (1997-04-01), Bennett et al.
patent: 5627267 (1997-05-01), Lyman et al.
patent: 5650504 (1997-07-01), Bartley et al.
patent: 5716934 (1998-02-01), Bartley et al.
patent: 5738844 (1998-04-01), Beckmann et al.
patent: 5795734 (1998-08-01), Flanagan et al.
patent: 5798448 (1998-08-01), Caras et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 6001964 (1999-12-01), Gaynor et al.
patent: 6864227 (2005-03-01), Wang et al.
patent: 2004/0180823 (2004-09-01), Pasquale et al.
patent: 2004/0247592 (2004-12-01), Roifman et al.
patent: WO90/00192 (1990-01-01), None
patent: WO94/11020 (1994-05-01), None
patent: WO95/06065 (1995-03-01), None
patent: WO96/01839 (1996-01-01), None
patent: WO96/02645 (1996-02-01), None
patent: WO96/09384 (1996-03-01), None
patent: WO96/10911 (1996-04-01), None
patent: WO96/13518 (1996-05-01), None
patent: WO96/17925 (1996-06-01), None
patent: WO96/23000 (1996-08-01), None
patent: WO96/26958 (1996-09-01), None
patent: WO96/36713 (1996-11-01), None
patent: WO97/36919 (1997-10-01), None
patent: WO99/08696 (1999-02-01), None
patent: WO99/10495 (1999-03-01), None
patent: WO99/45121 (1999-09-01), None
patent: WO99/52541 (1999-10-01), None
patent: WO99/67285 (1999-12-01), None
patent: WO00/30673 (2000-06-01), None
patent: WO00/37500 (2000-06-01), None
patent: WO01/08636 (2001-02-01), None
patent: WO02/26827 (2002-04-01), None
patent: WO2004/028551 (2004-04-01), None
patent: WO2004/080425 (2004-09-01), None
patent: WO2004/091375 (2004-10-01), None
patent: WO2006/081418 (2006-08-01), None
patent: WO2008/100288 (2008-08-01), None
Pasquale E.B., Eph—ephrin promiscuity is now crystal clear. Nature Neuroscience 7, 417-418 (2004).
U.S. Appl. No. 60/647,852, filed Jan. 27, 2005, Pasquale, et al.
Aasland, et al., “Normalization of nomenclature for peptide motifs as ligands of modular protein domains”FEBS Lett. (2002) 513(1): 141-144.
Adams, et al., “Eph receptors and ephrin ligands: essential mediators of vascular development”Trends Cardiovasc. Med. (2004) 10(5): 183-188.
Andrews, et al., “Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis”Oncogene(1994) 9: 1461-1467.
Aoki, et al., “Eph receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway”J. Biol. Chem. (2004) 279(31): 32643-32650.
Arap, et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model”Science(1998) 279(5349): 377-380.
Arap, et al., “Targeting the prostate for destruction through a vascular address”PNAS USA(2002) 99(3): 1527-1531.
Batlle, et al., “EphB receptor activity suppresses colorectal cancer progression”Nature(2005) 435: 1126-1130.
Battaglia, et al., “EphB receptors and ephrin-B ligands regulate spinal sensory connectivity and modulate pain processing”Nat. Neurosci. (2003) 6(4): 339-340.
Bennett, et al., “Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk”PNAS USA(1995) 92(6): 1866-1870.
Blanco, et al., “Formation and stability of beta-hairpin structures in polypeptides”Curr. Opin. Struct. Biol. (1998) 8(1): 107-111.
Bork et al., “Go hunting in sequence database but watch out for the traps”Trends in Genetics(1996) 12(10): 425-427.
Bork, “Powers and pitfalls in sequence analysis: The 70% hurdle”Genome Res. (2000) 102: 398-400.
Brantely-Sieders, et al., “Eph receptor tyrosine kinases in angiogenesis: form development to disease”Angiogenesis(2004) 7(1): 17-28.
Brantely-Sieders, et al., “Eph receptor tyrosine kinases in tumor and tumor microenvironment”Curr Pharma Design(2004) 10: 3431-3442.
Brenner, “Errors in genome functions”Trends in Genetics(1999) 15(4): 132-133.
Carles-Kinch, et al., “Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior”Cancer Res. (2002) 62(10): 2840-2847.
Chang, et al., (1986) NCBI Accession No. P01153, p. 1. [retrieved on Feb. 3, 2006]. Retrieved from the Internet: <http://www.ncbi.nIm.nih.gov/entrez/viewer.fcgi?db=protein&val=123907>.
Chrencik, et al., “Structure and Biophyscial Characterization of the EphB4-EphrinB2 Protein-Protein Interaction and Receptor Specificity”J. Biol. Chem. (2006) 281(38): 28185-28192.
Chrencik, et al., “Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity”Structure(2006) 14(2): 321-330.
Conover, et al., “Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone”Nat. Neurosci. (2000) 3(11): 1091-1097.
Cwirla, et al., “Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine”Science(1997) 276(5319): 1696-1699.
Dail, et al., “Eph receptors inactivate-R-Ras through different mechanisms to achieve cell repulsion”J. Cell Sci. (2006) 119(Pt. 7): 1244-1254.
Daniel, et al., “ELK and LERK-2 in developing kidney and microvascular endothelial assembly”Kidney Int. Suppl. (1996) 57: S73-S81.
Davis, et al., “Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity”Science(1994) 266(5186): 816-819.
Devlin, et al., “Random peptide libraries: a source of specific protein binding molecules”Science(1990) 249: 404-406.
Dodelet, et al., “Eph receptors and ephrin ligands: embryogenesis to tumorigenesis”Oncogene(2000) 19(49): 5614-5619.
Doerks, et al., “Protein annotation' detective work for function prediction”Trends in Genetics(1998) 14(6): 248-250.
Dohn, et al., “Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis”Oncogene(2001) 20(45): 6503-6515.
Dottori, et al., “EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract”PNAS USA(1998) 95: 13248-13253.
Dvorak, et al., “Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules”Am. J. Pathol. (1988) 133: 95-109.
Dybwad, et al., “Increased serum and synovial fluid antibodies to immunoselected peptides in patients with rheumatoid arthritis”Annals of Rheumatoid Diseases(1996) 55: 437-441.
Easty, et al., “Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis”Int. J. Cancer(1995) 60: 129-136.
Easty, et al., “Cytokine B61 as a growth factor for metastatic melanomas and increasing expression of its receptor Eck during melanoma progression”Proc. Am. Asso. Cancer Mtng. (1994) vol. 35 (Abstract; 85thAnnual Meeting, American Association for Cancer Research, San Francisco, CA, Apr. 10-13, 1994).
Easty, et al., “Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression”Cancer Res. (1995) 55: 2528-2532.
Eberhart, et al., “EphA4 constitutes a population-specific guidance cue for motor neurons”Dev. Biol. (2002) 247: 89-101.
Ellerby, et al., “Anti-cancer activity of targeted pro-apoptotic peptides”Nat. Med. (1999) 5(9): 1032-1038.
Ellis, et al., “Embryo brain kinase: a novle gene of the eph/elk receptors tyrosine kinase family”Mechanisms Devel. (1995) 52: 319-341

Affiliated with

Also associated with

Rating

EphB receptor-binding peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EphB receptor-binding peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EphB receptor-binding peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2723960